Descartes-08 CAR-T Cells in Generalized Myasthenia Gravis (MG)

Updated 06/21/2024

Status Recruiting

Clinical Trial Summary

This is a Phase IIb study to evaluate the safety and preliminary efficacy of Descartes-08 CAR T-cells in patients with Generalized Myasthenia Gravis

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04146051
Study type	Interventional
Source	Cartesian Therapeutics
Contact	Study Trial Central Mailbox
Phone	302-648-6497
Email	trials@cartesiantx.com
Status	Recruiting
Phase	Phase 2
Start date	December 4, 2019
Completion date	March 31, 2026

See also
	Status	Clinical Trial	Phase
	Completed	`NCT02565576` - Safety,Tolerability,Pharmacokinetics and Efficacy of CFZ533 in Moderate to Severe Myasthenia Gravis	Phase 2
	Completed	`NCT04115293` - Safety, Tolerability, and Efficacy of Zilucoplan in Subjects With Generalized Myasthenia Gravis	Phase 3
	Recruiting	`NCT05737160` - Study of Telitacicept in Generalized Myasthenia Gravis	Phase 3
	Recruiting	`NCT04224506` - A Pilot Study to Explore the Role of Gut Flora in Myasthenia Gravis
	Recruiting	`NCT06455709` - Markers of Favorable Response to Complement Inhibitors Therapy
	Recruiting	`NCT04431895` - Safety And Efficacy Of Tofacitinib In Patients With Refractory Myasthenia Gravis: A Pilot Study	Early Phase 1
	Recruiting	`NCT05067348` - Efficacy and Safety of Tocilizumab in the Treatment of Generalized Myasthenia Gravis	Phase 2
	Withdrawn	`NCT03165435` - A Study to Evaluate the Efficacy of CV-MG01 (Myasterix) in Myasthenia Gravis	Phase 2/Phase 3
	Recruiting	`NCT05214612` - Predictors and Prognostic Factors of Myasthenia Gravis Outcome
	Recruiting	`NCT05868837` - Rituximab EfFicacy IN MyasthEnia Gravis (REFINE)	Phase 3
	Recruiting	`NCT06282159` - A Phase 2 Study to Evaluate DNTH103 in Adults With Generalized Myasthenia Gravis (MAGIC)	Phase 2
	Completed	`NCT03759366` - A Phase 3 Open-Label Study of Eculizumab in Pediatric Participants With Refractory Generalized Myasthenia Gravis (gMG)	Phase 3
	Completed	`NCT02473952` - A Study to Evaluate the Efficacy and Safety of IGIV-C in Symptomatic Subjects With Generalized Myasthenia Gravis	Phase 2
	Completed	`NCT00683969` - A Study to Assess the Effect of CellCept (Mycophenolate Mofetil) and Reduced Corticosteroids in Controlling Symptoms of Myasthenia Gravis	Phase 3
	Completed	`NCT03304054` - Study to Evaluate Amifampridine Phosphate in Patients With MuSK-MG	Phase 3
	Recruiting	`NCT05716035` - Open-Label Extension of Tocilizumab in Subjects With Generalized Myasthenia Gravis	Phase 2/Phase 3